Price (delayed)
$0.589
Market cap
$69.57M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.09
Enterprise value
$119.89M
Gritstone bio, Inc., a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. Gritstone develops its products by leveraging two key pillars—first,
There are no recent dividends present for GRTS.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.